Metronomic cyclophosphamide was also used in a mouse model of pancreatic cancer in combination with another vegfr2 inhibitor (SU5416) or two different inhibitors of matrix metalloproteinases 10. This evidence concerns the gene KDR and pancreatic neoplasm.